Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-03-08 2:15 pm Sale |
2023-02-28 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BlackRock Inc. BLK |
3,427,741 4.900% |
-153,938 (-4.30%) |
Filing |
| 2023-02-14 4:08 pm Sale |
2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
HHLR ADVISORS LTD. | 2,623,924 7.600% |
-296,099 (-10.14%) |
Filing History |
| 2023-02-09 11:25 am Purchase |
2022-12-30 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
The Vanguard Group | 3,226,891 9.340% |
336,183 (+11.63%) |
Filing History |
| 2023-02-03 11:51 am Sale |
2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
PICTET ASSET MANAGEMENT SA | 1,234,193 3.570% |
-2,314,456 (-65.22%) |
Filing History |
| 2023-02-01 4:54 pm Purchase |
2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BlackRock Inc. BLK |
3,581,679 5.200% |
15,697 (+0.44%) |
Filing |
| 2022-09-08 1:43 pm Purchase |
2022-08-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BlackRock Inc. BLK |
3,565,982 5.100% |
82,130 (+2.36%) |
Filing |
| 2022-02-14 10:56 am Sale |
2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
AMERIPRISE FINANCIAL INC AMP |
285 0.000% |
-2,370,951 (-99.99%) |
Filing History |
| 2022-02-10 11:07 am Purchase |
2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
PICTET ASSET MANAGEMENT SA | 3,548,649 5.150% |
3,548,649 (New Position) |
Filing History |
| 2022-02-10 08:22 am Purchase |
2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
The Vanguard Group | 2,890,708 8.530% |
354,287 (+13.97%) |
Filing History |
| 2022-01-27 5:13 pm Unchanged |
2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BlackRock Inc. BLK |
3,483,852 10.300% |
0 (Unchanged) |
Filing |
| 2022-01-26 09:16 am Sale |
2021-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BlackRock Inc. BLK |
3,483,852 10.300% |
-34,037 (-0.97%) |
Filing |
| 2021-11-24 3:40 pm Unchanged |
2021-10-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BlackRock Inc. BLK |
3,517,889 10.400% |
0 (Unchanged) |
Filing |
| 2021-11-10 09:43 am Purchase |
2021-10-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
BlackRock Inc. BLK |
3,517,889 10.400% |
3,517,889 (New Position) |
Filing |
| 2021-02-16 4:24 pm Purchase |
2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
HHLR ADVISORS LTD. | 2,920,023 9.200% |
1,024,135 (+54.02%) |
Filing History |
| 2021-02-16 1:29 pm Sale |
2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
ArrowMark Colorado Holdings LLC | 1,156,338 3.700% |
-118,086 (-9.27%) |
Filing History |
| 2021-02-12 12:08 pm Purchase |
2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
AMERIPRISE FINANCIAL INC AMP |
2,371,236 7.500% |
1,221,658 (+106.27%) |
Filing History |
| 2021-02-10 11:10 am Purchase |
2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
The Vanguard Group | 2,536,421 8.020% |
1,334,968 (+111.11%) |
Filing History |
| 2020-11-05 4:55 pm Sale |
2020-10-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA |
Consonance Capital Management LP | 1,252,229 3.990% |
-988,550 (-44.12%) |
Filing History |